Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 2/20 | 0.50 |
| ▸ | CNR2 | P34972 | 2/20 | 0.50 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | HTR3A | P46098 | 7/20 | 0.47 |
| ▸ | ICMT | O60725 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.46 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17176358 | 0.84 | HTR3A (0.60) | POLBCNR1CNR2KCNH2HTR3A | |
| SCHEMBL30564140 | 0.84 | SMN1; SMN2 (0.56) | POLBCNR1CNR2CREBBPHTR3A | |
| SCHEMBL17176243 | 0.83 | HTR3A (0.58) | POLBCNR1CNR2CREBBPKCNH2 | |
| SCHEMBL20379523 | 0.82 | SCN9A (0.46) | POLBCNR1CNR2HTR3AICMT | |
| SCHEMBL7275971 | 0.81 | KDM4E (0.55) | POLBKCNH2NPC1RAB9AKMT2A | |
| SCHEMBL17176319 | 0.81 | HTR3A (0.58) | POLBCNR1CNR2CREBBPHTR3A | |
| SCHEMBL17176279 | 0.80 | CREBBP (0.73) | POLBCREBBPHTR3ANPC1RAB9A | |
| SCHEMBL4494230 | 0.76 | CNR2 (0.61) | CNR1CNR2HTR3AICMT | |
| SCHEMBL2817707 | 0.75 | ALDH1A1 (0.50) | CNR1CNR2HTR3AKMT2A | |
| SCHEMBL24182183 | 0.75 | CNR2 (0.47) | POLBCNR1CNR2KCNH2HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160185801-A1 | 5-HT3 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL (JP) | 2016-06-30 | — | — | US | disclosed |
| US-9303045-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-04-05 | — | — | US | disclosed |
| US-20150291624-A1 | 5-HT3 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185801-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR5A, HTR3B | POLB 3362/4885CNR1 37/4885CNR2 47/4885 |
| US-20150291624-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR5A, HTR3B | POLB 3362/4885CNR1 37/4885CNR2 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.